Abstracts tagged "anti-TNF therapy"

Abstract Number: 2876 • 2015 ACR/ARHP Annual Meeting
Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
Maxime Dougados¹, Gina Bergman², Walter Maksymowych³, Sean P. Curtis², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Paris-Descartes University, Paris, France, ²Merck & Co., Inc., Kenilworth, NJ, ³University of Alberta, Edmonton, AB, Canada, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Subgroup analyses can be used to investigate the size and direction of treatment effects across a range of demographic and disease characteristics. The purpose…
Abstract Number: 107 • 2015 ACR/ARHP Annual Meeting
FCGR3A-158V/F Polymorphism Is Associated with a Lower Response Rate to Tumor Necrosis FactorÂ Î± Blockers in Early Axial Spondyloarthritis: Data from the DESIR Cohort
Cécile LUXEMBOURGER¹, Anna Molto², Pascal Claudepierre³, Delphine Nigon¹, Alain G. Cantagrel¹, Maxime Dougados⁴, Arnaud CONSTANTIN¹ and Adeline Ruyssen Witrand⁵, ¹Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ²Hopital Cochin, Paris Descartes University, Paris, France, ³Hôpital Henri Mondor, Créteil, France, ⁴Service de Rhumatologie B, GHU Cochin, F-75014 France, PARIS, France, ⁵Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose: The rs396991 polymorphism of FCGR3A alters the Fcγ Receptor Type IIIA function by enhancing or diminishing the affinity to the Fc of immunoglobulins (1)…
Abstract Number: 671 • 2015 ACR/ARHP Annual Meeting
Discrepancy Between Patients and Physicians Acceptable Symptomatic States in Axial Spondyloarthritis: Findings from the RAPID-AxSpA Study
Maxime Dougados¹, Owen Davies², Tommi Nurminen³, Geoffroy Coteur⁴ and Laure Gossec⁵, ¹Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ²UCB Pharma, Slough, United Kingdom, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵Sorbonne Universités, UPMC Univ Paris 06 GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière Rheumatology Department, Paris, France
Background/Purpose: Discordance between patient (pt) and physician (phy) assessment of disease activity (DA) in spondyloarthritis (SpA) is recognized, with phys tending to score DA less…
Abstract Number: 1638 • 2015 ACR/ARHP Annual Meeting
Early Response As a Predictor of Long-Term Remission in DMARD-Naïve Patients with Severe, Active and Progressive Rheumatoid Arthritis Treated with Certolizumab Pegol in Combination with Methotrexate
Michael Weinblatt¹, Clifton Bingham², Gerd Burmester³, VP Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Daljit Tatla⁸, Catherine Arendt⁹, Irina Mountian¹⁰, Brenda VanLunen¹¹ and Paul Emery¹², ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Hospital for Special Surgery, New York, NY, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ⁷University Hospital, Maastricht, Netherlands, ⁸8010 Arco Corporate Dr, UCB Pharma, Raleigh, NC, ⁹Global Medical Affairs, UCB Pharma, Brussels, Belgium, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In established rheumatoid arthritis (RA), a lack of response to treatment with certolizumab pegol (CZP) at early timepoints is associated with a low probability…
Abstract Number: 2752 • 2015 ACR/ARHP Annual Meeting
Profile of Joint Involvement over Time in Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Anti-TNF in a Real-World Setting
Algis Jovaisas¹, Michael Starr², Denis Choquette³, Michel Zummer⁴, Regan Arendse⁵, Dalton Sholter⁶, Rafat Faraawi⁷, Jude Rodrigues⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹, May Shawi¹⁰ and Karina Maslova¹⁰, ¹Capital North Therapeutics & Research, Ottawa, ON, Canada, ²Rheumatology, McGill University, Montreal, QC, Canada, ³Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Université de Montréal, Quebec, QC, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸Jude Rodrigues Medicine Professional Corporation, Windsor, ON, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: : Unlike rheumatoid arthritis (RA), the pattern of joint involvement in psoriatic arthritis (PsA) is usually asymmetric. Furthermore, PsA may demonstrate oligoarthritis or polyarthritis,…
Abstract Number: 2877 • 2015 ACR/ARHP Annual Meeting
What Is the Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
John Kelsall¹, Denis Choquette², Proton Rahman³, Regan Arendse⁴, Michelle Teo⁵, Isabelle Fortin⁶, J Antonio Avina-Zubieta⁷, Emmanouil Rampakakis^8,9, Eliofotisti Psaradellis⁹, Karina Maslova¹⁰, Brendan Osborne¹¹, Cathy Tkaczyk¹¹, Francois Nantel¹² and Allen J Lehman¹⁰, ¹Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ²Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ³Medicine, Memorial University, St John's, NF, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ⁶Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁷Arthritis Research Canada, Richmond, BC, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Enthesitis is characterized by inflammation at the insertion of ligaments, tendons, joint capsule, or fascia to bone, and represents a well-known characteristic feature of…
Abstract Number: 122 • 2015 ACR/ARHP Annual Meeting
General Practitioners’ Perceptions of Methotrexate and Anti-TNF Therapies: A Qualitative Study
Martin Soubrier¹, Sylvain Mathieu² and Elise Berthet³, ¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Rheumatology Department, CHU clermont-Ferrand, Clermont-Ferrand, France, ³Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France
Background/Purpose: Remission of disease is the primary goal in chronic inflammatory arthritis, especially in rheumatoid arthritis. Traditional disease-modifying drugs like methotrexate and anti-tumor necrosis factor…
Abstract Number: 681 • 2015 ACR/ARHP Annual Meeting
Impact of Disease Duration on Patient Reported and Clinical Outcomes in Patients with Ankylosing Spondylitis Treated with Anti-TNF: An Analysis from a Prospective, Observational Registry
Michael Starr¹, Michel Zummer², Denis Choquette³, Boulos Haraoui⁴, Dalton Sholter⁵, Regan Arendse⁶, Isabelle Fortin⁷, Louis Bessette⁸, Proton Rahman⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Allen J Lehman¹², Karina Maslova¹², Brendan Osborne¹³, Francois Nantel^14,15 and Cathy Tkaczyk¹³, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁹Medicine, Memorial University, St John's, NF, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁴Schering Plough Canada Inc., Janssen Inc., Kirkland, QC, QC, Canada, ¹⁵19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have shown that treatment outcomes are affected by disease-related aspects (e.g., disease severity and chronicity, treatment type and intensity) and patient-related factors…
Abstract Number: 1669 • 2015 ACR/ARHP Annual Meeting
Serum Survivin Predicts Responses to Treatment in Active Rheumatoid Arthritis
Adrian Levitsky¹, Malin C. Erlandsson², Ronald F. van Vollenhoven¹ and Maria I. Bokarewa², ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Survivin is an oncological biomarker. In rheumatoid arthritis (RA), elevated serum survivin is common and has been used to predict disease onset and progressive…
Abstract Number: 2758 • 2015 ACR/ARHP Annual Meeting
Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, John Isaacs³, Ann W. Morgan⁴, Anthony Wilson⁵, Kimme L. Hyrich⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ⁶Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Up to 40% of RA patients on anti-TNF agents fail to respond either due to primary or secondary inefficacy. One explanation is immunogenicity leading…
Abstract Number: 2879 • 2015 ACR/ARHP Annual Meeting
What Is the Location of Dactylitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
Regan Arendse¹, Proton Rahman², Denis Choquette³, J Antonio Avina-Zubieta⁴, Michel Zummer⁵, Milton F. Baker⁶, Jacqueline Stewart⁷, Isabelle Fortin⁸, Michelle Teo⁹, Emmanouil Rampakakis¹⁰, Eliofotisti Psaradellis¹¹, Brendan Osborne¹², Cathy Tkaczyk¹², Karina Maslova¹³, Francois Nantel¹⁴ and Allen J Lehman¹³, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Computer Sciences, Memorial University of Newfoundland, St. John's, NF, Canada, ³Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁵Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ⁶VIHA, Victoria, BC, Canada, ⁷Penticton Regional Hospital, Penticton, BC, Canada, ⁸Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁹Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ¹⁰JSS Medical Research, St-Laurent, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Dactylitis is one of the most commonly reported features in spondyloarthritis. It has been hypothesized that dactylitis is a functional enthesitis at the proximal…
Abstract Number: 446 • 2015 ACR/ARHP Annual Meeting
Low Disease Activity at 12 Weeks and 24 Weeks Is Predictive of Normalized Health-Related Quality of Life in Methotrexate-Experienced Patients with Active Rheumatoid Arthritis Treated with Intravenous Golimumab Plus Methotrexate
Clifton O. Bingham III¹, Michael Weinblatt², Rene Westhovens³, Lilianne Kim⁴, Chenglong Han⁵, Stephen Xu⁴, Kim Hung Lo⁴, Kezhen L. Tang⁴, Elizabeth C. Hsia^4,6, Dennis Parenti⁷ and Shelly Kafka⁷, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³UZ Gasthuisberg, Leuven, Belgium, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Global Services, LLC, Malvern, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Previous analyses in patients (pts) with rheumatoid arthritis (RA) have evaluated the relationship between controlling disease activity and achieving long-term improvements in health-related quality…
Abstract Number: 701 • 2015 ACR/ARHP Annual Meeting
Is Skin Disease More Important to Women or Men in the Assessment of Disease Activity in Psoriatic Arthritis?
Maqbool Sheriff¹, Michel Zummer², J Antonio Avina-Zubieta³, Proton Rahman⁴, Wojciech Olszynski⁵, Michael Starr⁶, Philip Baer⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Cathy Tkaczyk¹⁰, Brendan Osborne¹⁰, Karina Maslova¹¹, Francois Nantel¹² and Allen J Lehman¹¹, ¹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ²Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ³Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁴Rheumatology, St. Clare's Mercy Hospital, St. John's, NF, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Rheumatology, McGill University, Montreal, QC, Canada, ⁷Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Patient global assessment of disease activity (PtGA) is a standard outcome measure used both in randomized controlled trials and in clinical practice to ascertain…
Abstract Number: 1700 • 2015 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis in Ankylosing Spondylitis. Does It Really Exist and Which Are the Effects of Treatments? a Systematic Review
Clément Prati¹, Céline Demougeot², Xavier Guillot² and Daniel Wendling³, ¹Service de Rhumatologie, CHRU J Minjoz, Besançon, France, ²EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, ³Université de Franche-Comté, Besançon, France
Background/Purpose: Accelerated atherosclerosis and increased cardiovascular morbidity and mortality have been associated with ankylosing spondylitis (AS). Noninvasive angiological methods have been developped to evaluate endothelial…
Abstract Number: 2768 • 2015 ACR/ARHP Annual Meeting
Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Wenhui Wei¹, Emma Sullivan², Chieh-I Chen³, James Piercy² and Stuart Blackburn², ¹Sanofi-Aventis, Bridgewater, NJ, ²Adelphi Real World, Manchester, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among rheumatoid arthritis (RA) patients who progress beyond their first biologic disease-modifying antirheumatic drug (bDMARD), in-class cycling between different tumor necrosis factor inhibitors (TNFi)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].